Get the Stockscreener App
65.10
1.56%
1.00
Pre-market:
65.40
0.30
+0.46%
Arrowhead Pharmaceuticals Inc stock is traded at $65.10, with a volume of 1.85M.
It is up +1.56% in the last 24 hours and down -4.35% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
See More
Previous Close:
$64.10
Open:
$65.03
24h Volume:
1.85M
Relative Volume:
0.62
Market Cap:
$9.12B
Revenue:
$1.09B
Net Income/Loss:
$233.57M
P/E Ratio:
42.32
EPS:
1.5382
Net Cash Flow:
$327.01M
1W Performance:
+5.66%
1M Performance:
-4.35%
6M Performance:
+132.50%
1Y Performance:
+280.48%
1-Day Range:
$62.96
$66.05
1-Week Range:
$60.88
$67.15
52-Week Range:
$9.57
$76.76
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
65.10 | 8.98B | 1.09B | 233.57M | 327.01M | 1.5382 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference - Yahoo Finance
Rafferty Asset Management LLC Sells 27,546 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Fisher Asset Management LLC Acquires 602,139 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals at TD Cowen Conference: Strategic Insights in Cardiometabolic Focus - Investing.com Canada
Arrowhead Pharmaceuticals, Inc. (ARWR) Competitors - Meyka
ARWR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation As Its RNAi Pipeline Advances To Phase 3 With Big Pharma Partners - simplywall.st
Erste Asset Management GmbH Has $2.47 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. $ARWR Position Increased by JPMorgan Chase & Co. - MarketBeat
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Cooling Share Price And Strong Long-Term Returns - Yahoo Finance
Arrowhead’s Expanded 2026 Conference Circuit and Phase 3 RNAi Pipeline Might Change The Case For Investing In Arrowhead Pharmaceuticals (ARWR) - Sahm
Vanguard Group Inc. Has $553.08 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Net current asset value per share of Arrowhead Pharmaceuticals, Inc. – DUS:HDP1 - TradingView
Arrowhead Pharmaceuticals Achieves 201.24% Return, Establishing It as a Multibagger in Biotechnology - Markets Mojo
Arrowhead Pharmaceuticals, Inc. (ARWR): An Investor Outlook on Its 28.86% Potential Upside - DirectorsTalk Interviews
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events - Business Wire
Responsive Playbooks and the ARWR Inflection - Stock Traders Daily
Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Raised by King Luther Capital Management Corp - MarketBeat
Reviewing Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Nutra Pharma (OTCMKTS:NPHC) - Defense World
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million - AOL.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Presents a High-Growth, Technical Breakout Opportunity - ChartMill
Rhumbline Advisers Buys 11,115 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - Defense World
Aberdeen Group plc Sells 439,601 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)'s Familial Chylomicronemia Syndrome Likely Limited - Finviz
Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)’s Familial Chylomicronemia Syndrome Likely Limited - Yahoo Finance
Strategic Shift in Biopharma Dealmaking - Intellectia AI
Fundamentals Check: Can Arrowhead Pharmaceuticals Inc weather a recessionEarnings Growth Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Arrowhead Pharmaceuticals (ARWR) Investor Outlook: Exploring the 27.49% Upside Potential - DirectorsTalk Interviews
Piper Sandler highlights Arrowhead Pharmaceuticals, Inc. (ARWR) pipeline with upcoming phase III hypertriglyceridemia data - MSN
Public Sector Pension Investment Board Grows Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
AlphaQuest LLC Sells 30,501 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Will Arrowhead Pharmaceuticals Inc. stock benefit from automationJuly 2025 Review & Weekly Chart Analysis and Trade Guides - mfd.ru
What’s the beta of Arrowhead Pharmaceuticals Inc. stockWeekly Trade Recap & Accurate Entry and Exit Point Alerts - mfd.ru
What are Arrowhead Pharmaceuticals Inc.’s recent SEC filings showingProfit Target & Capital Protection Trading Alerts - mfd.ru
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens - Benzinga
Is Arrowhead Pharmaceuticals Inc. gaining market shareTrade Risk Assessment & Verified Momentum Stock Watchlist - mfd.ru
Zacks Research Issues Negative Estimate for ARWR Earnings - MarketBeat
Johnson Investment Counsel Inc. Makes New $781,000 Investment in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Equities Analysts Issue Forecasts for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality - simplywall.st
The Strong Earnings Posted By Arrowhead Pharmaceuticals (NASDAQ:ARWR) Are A Good Indication Of The Strength Of The Business - 富途牛牛
Understanding the Setup: (ARWR) and Scalable Risk - Stock Traders Daily
ARWR: Strong Start for REDEMPLO Commercialization - Smartkarma
ARWR: Strong Start for REDEMPLO Commercialization… - Yahoo Finance
Arrowhead Joins S&P 400 As Profitability Shifts Investor Focus - Sahm
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Arrowhead Pharma (ARWR) Receives Buy Rating from HC Wainwright | - GuruFocus
Breaking Down Arrowhead Pharma: 18 Analysts Share Their Views - Benzinga
Goldman Sachs Maintains Neutral on ARWR Arrowhead Pharmaceuticals Feb 2026 - Meyka
Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR) - TechStock²
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):